Nunn Jason Raleigh — SEC Form 4 filings
SEC reporting owner CIK 1444319. 10 Form 4 filings on record with FilingPulse; latest filed 2026-09-04.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-05-17 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 945,510 shares, $16,199,986 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: purchase of 441,176 shares @ $17.00 ($7,499,992) in Zenas BioPharma, Inc., filed 2024-09-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | Director | 4 | 3 legs · 945,510 sh · $16,199,986 | — | 7 |
| Regulus Therapeutics Inc. (RGLS) | Director | 4 | — | — | 12 |
| Addex Therapeutics Ltd. (ADXN) | Director | 1 | — | — | 4 |
| TREVENA INC (TRVN) | Director | 1 | — | — | 1 |
Form 4 filings — Nunn Jason Raleigh
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-04 | 4 | Addex Therapeutics Ltd. (ADXN) | Disposition to issuer (D): 219,561 @ $0 · Grant/award (A): 219,561 @ $0 · Disposition to issuer (D): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | Zenas BioPharma, Inc. (ZBIO) | Purchase (P): 63,158 @ $19 | EDGAR |
| 2025-06-27 | 4 | Regulus Therapeutics Inc. (RGLS) | Disposition to issuer (D): 62,500 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · +3 more | EDGAR |
| 2025-06-12 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) | Conversion (C): 1,505,388 · Purchase (P): 441,176 @ $17 · Conversion (C): 669,061 · Purchase (P): 441,176 @ $17 · Grant/award (A): 37,000 (derivative) @ $0 · Conversion (C): 13,071,439 (derivative) · +1 more | EDGAR |
| 2024-06-14 | 4 | TREVENA INC (TRVN) | Grant/award (A): 13,700 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1444319 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →